B of A Securities Maintains Buy on CG Oncology, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Charlie Yang has reiterated a Buy rating for CG Oncology (NASDAQ:CGON) with a maintained price target of $65.
October 08, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Charlie Yang has reiterated a Buy rating for CG Oncology with a maintained price target of $65, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $65 price target by a reputable analyst suggests positive sentiment and potential upside for CG Oncology's stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100